Saturday - June 7, 2025
Update on CAPItello-280 Phase III Trial of TRUQAP (capivasertib) in Metastatic Castration-Resistant Prostate Cancer
April 30, 2025
WILMINGTON, Delaware, April 30 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Update on CAPItello-280 Phase III trial of TRUQAP (capivasertib) in metastatic castration-resistant prostate cancer

AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of TRUQAP (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with p . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products